Management of neutropenia & fever: antibiotic policy

Neutropenia is defined as a neutrophil count of <1 x 10⁹/L and patients who are neutropenic are vulnerable to overwhelming infection. The frequency and severity of infective episodes correlates with the degree and duration of neutropenia and is particularly marked in children whose neutrophil count is below 0.5 x 10⁹/l.

This guideline should be read in conjunction with the assessment, diagnosis and management of Neutropenic Sepsis, Best Practice Statement, publication date: September 2012 (see Section 6.1).

3.1   The diagnosis and management of febrile neutropenia will be directed by the Consultant/Associate Specialist or a senior member of the medical team.

3.2   The Medical/Nursing team will be responsible for admitting, assessing, investigating and administrating treatment, and monitoring response.

None.

(see appendix 2 for antibiotic dosing advice)

 First Line Antimicrobial Therapy

• Suspected/Confirmed Neutropenic Patients

First line empirical therapy in neutropenic patients is with Piperacillin/Tazobactam and Gentamicin in the absence of positive blood cultures which would indicate alternative antibiotics. Piperacillin/Tazobactam is a penicillin based antibiotic and penicillin allergy should be excluded. Patients known to be colonised with ESBL producing organisms should receive Meropenem.

• Prescribe Piperacillin/Tazobactam according to pharmacy dose banding chart.
• Gentamicin requires caution in patients at risk of renal impairment. However, it is extremely unlikely that one single dose of Gentamicin will do harm and a single dose should be given and levels measured before any subsequent doses.
• Patients initially started on Piperacillin/Tazobactam and Gentamicin can stop Gentamicin if subsequently shown not to be neutropenic and they are neither septic or shocked.
• NB Piperacillin increases the risk of toxicity when given with Methotrexate. For any patient imminently due IV Methotrexate at any dose >500mg/m² or who is post IV Methotrexate and has not cleared to acceptable levels, prescribe Meropenem as first line empirical therapy.
• Antibiotic cover for line-related infection:
• Teicoplanin should be added to the initial therapy only if there is a proven or a very high suspicion of central line infection. Teicoplanin is preferable to vancomycin for patients receiving other nephrotoxic drugs and most haemato/oncology patients are on other nephrotoxic drugs. Factors suggesting line infection include:
  • Local Sepsis: Erythema at exit site or skin tunnel; pain over tunnel or on moving that arm/shoulder
  • Previously documented catheter related sepsis involving the current central venous line
  • Rigor or fever after flushing line (within 4 hours)
  • Blood culture positive for an organism associated with the related infection

  Vancomycin, rather than Teicoplanin should only be used in patients suspected to have a line related infection and who are septicaemic.

Second Line Antimicrobial Therapy

• Patients who remain pyrexial after 72 hours of empirical therapy should change to second line therapy. Second line therapy is with Meropenem with or without Gentamicin.
• Patients who remain pyrexial at 5 days and who are or have been persistently neutropenic with no evidence of line related infection should have AmBisome This should be discussed with the consultant responsible for the care of the patient.

Penicillin Allergy

• Serious allergy is one that causes an anaphylactic or urticarial reaction. 10% of patients with reactions to penicillin-based antibiotics will also have a reaction with cephalosporins.
• Patients who have had an allergic reaction classified as serious should receive Ciprofloxacin & Vancomycin.
• If ciprofloxacin has been given as prophylaxis, discuss treatment with Consultant Microbiologist on call.

Duration of Antimicrobial Treatment

This depends on the degree and duration of neutropenia and the organism cultured, but as a general rule:

• Patients who are blood culture negative; stop antibiotics after 48 hours of apyrexia if the patient is well and if the blood cultures are negative.
• Patients who are culture positive: this depends on the organism and the degree and duration of neutropenia. Discuss the duration of antibiotics with microbiology/ID. Preferably repeat blood cultures should be documented to have no growth.
• Gentamicin should not be given for more than 7 days. If the child needs additional gram negative non-aminoglycoside antimicrobial cover, discuss with the microbiologist.

• First line therapy for patients who are known not to be neutropenic or expected not to be neutropenic, and considered low risk for developing severe sepsis, should be single agent Piperacillin/Tazobactam.
• Patients started on both Piperacillin/Tazobactam and Gentamicin should stop the aminoglycoside if subsequently found not to be neutropenic, if neither septic nor shocked.

Antipyrexial Treatment

Once cultures have been taken and antibiotics started it is acceptable to treat the fever with Paracetamol.  Do not give non-steroidal anti-inflammatories such as ibuprofen. Non-steroidals are contraindicated because of their effect on platelet function.

Chemotherapy

Withhold oral chemotherapy for Acute Leukaemia patients. Refer to individual treatment protocol /guidelines for other haemato/oncology patients to establish if chemotherapy should be stopped temporarily in the neutropenic patient.  Note: In certain protocols, chemotherapy is continued even in the presence of neutropenic fever. Discuss with consultant. 

Examination

The child should be examined daily for signs of infection including sites such as the mouth, axillae, ears, perineum and central catheter site.

Co-trimoxazole as PCP Prophylaxis

Continue co-trimoxazole prophylaxis whilst other antibiotics are being given unless the patient is receiving high dose co-trimoxazole intravenously or consultant thinks that co-trimoxazole should be temporarily discontinued to allow count recovery. Prophylaxis need not be given intravenously but can be temporarily withheld in patients who are nil by mouth.

This SOP will be reviewed in 24 months time.

None

NB Antibiotic doses in this guideline are appropriate for empirical treatment or sensitive organisms only. For any organism categorised as ‘I’ (Susceptible – increased exposure), seek further advice or refer to local policy for appropriate dose selection’ (see NHS GGC Clinical Guidelines Portal)

Appendix 2: Antibiotic dosing guidelines (pdf)